Hepatitis C New Drugs Review
21.0K views | +7 today
Follow
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

The Rise and Fall of the Fastest Growing Drug in the World - DailyFinance

The Rise and Fall of the Fastest Growing Drug in the World
DailyFinance
Initial estimates of Incivek's peak sales were astronomical, with some figures calling for sales as high as $5 billion.
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

May: Hepatitis C treatments | News | University of Bristol

May: Hepatitis C treatments | News | University of Bristol | Hepatitis C New Drugs Review | Scoop.it
RT @NIHR_CCF: #NIHR co-funded studies assess potential of #HepC treatments on transmission #WorldHepDay https://t.co/4yPXaZvtX4 https://t.c
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Focusing on patients and progress on World Hepatitis Day

Focusing on patients and progress on World Hepatitis Day | Hepatitis C New Drugs Review | Scoop.it
World Hepatitis Day is a unique opportunity to take stock of the recent advancements in new treatments and cures to combat versions of hepatitis.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

World Hepatitis Day 2016: Speaking out on hepatitis, the “silent killer”

World Hepatitis Day 2016: Speaking out on hepatitis, the “silent killer” | Hepatitis C New Drugs Review | Scoop.it
More than 400 people across the European Region die from viral #hepatitis-related causes every day #WorldHepDay https://t.co/izfSjb7FKi
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Perspectives Toward the Elimination of Hepatitis B | Speaking of Medicine

Perspectives Toward the Elimination of Hepatitis B | Speaking of Medicine | Hepatitis C New Drugs Review | Scoop.it
Professor Guangxiang (George) Luo discusses recent advances in antiviral drug development and hepatitis B immunization which hold great promise for achieving the WHO goal of eliminating viral hepatitis by 2030. The World Health Organization (WHO) has called for the elimination of viral hepatitis as a public health threat by 2030. This has inspired the scientific community, pharmaceutical industry, and government agencies to explore various strategies to achieve this ambitious goal in the next 15 years. The elimination of hepatitis B virus (HBV) infection in particular, was a topic of two recent meetings I attended. On April 27-28 the United States’ National Institutes of Health convened an NIH Workshop on Cures for Chronic Hepatitis B. A month later, I participated in a strategic discussion on prevention of HBV infection in China (organized by Professor Jidong Jia and Professor Hui Zhuang). Of the five causative agents of viral hepatitis (hepatitis A, B, C, D, and E), HBV and HCV
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Discovery of new Hepatitis C virus mechanism

Discovery of new Hepatitis C virus mechanism | Hepatitis C New Drugs Review | Scoop.it
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus (HCV) with the potential of improving pathological liver conditions. Using model mice, they confirme
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Expanding Access To Hepatitis C Treatment To All Who Need It

Expanding Access To Hepatitis C Treatment To All Who Need It | Hepatitis C New Drugs Review | Scoop.it
Jeffrey thought the battles in his life were over. But following his service in Iraq as a combat solider, Jeffrey fought drug addiction and was late
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

WHO: Hepatitis C

WHO: Hepatitis C | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C is a liver disease caused by the hepatitis C virus: the virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New medication shows promise against liver fibrosis in animal studies - ScienceBlog.com

New medication shows promise against liver fibrosis in animal studies - ScienceBlog.com | Hepatitis C New Drugs Review | Scoop.it
A new drug developed by scientists at the National Institutes of Health limits the progression of liver fibrosis in mice, a hopeful advance against a condition for which there is no current treatment and that often leads to serious liver disease in...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Microwave Coagulation/Ablation in Combination with Sorafenib Suppresses the Overgrowth of Residual Tumor in VX2 Liver Tumor Model - Wen-Tao Kong - Discovery Medicine

Microwave Coagulation/Ablation in Combination with Sorafenib Suppresses the Overgrowth of Residual Tumor in VX2 Liver Tumor Model - Wen-Tao Kong - Discovery Medicine | Hepatitis C New Drugs Review | Scoop.it
Objectives: Our study is to evaluate the effect of thermal ablation on residual VX2 tumor tissue and the efficiency of sorafenib as an adjuvant therapy after insufficient microwave coagulation (MWC) on a rabbit VX2 liver tumor model.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cenicriviroc (Tobira Therapeutics) Improves Liver Fibrosis  Phase 2b CENTAUR NASH Trial 

Cenicriviroc (Tobira Therapeutics) Improves Liver Fibrosis  Phase 2b CENTAUR NASH Trial  | Hepatitis C New Drugs Review | Scoop.it

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced results from CENTAUR, its Phase 2b clinical trial evaluating the efficacy and safety of cenicriviroc (CVC) for the treatment of NASH in 289 adults with liver fibrosis. Although the study did not meet its primary endpoint of a two-point reduction in the NAFLD Activity Score, CENTAUR did demonstrate a clinically and statistically significant improvement in fibrosis of at least one stage without worsening of NASH, one of two key secondary endpoints, after only one year of treatment. Regulators have recently identified this endpoint for Phase 3 studies to support a marketing application. CENTAUR is the first randomized study to evaluate this as a pre-specified endpoint.


About Cenicriviroc (CVC) CVC is an oral, once-daily, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways in NASH that cause liver damage and often lead to cirrhosis, liver cancer, or liver failure. Because of this unique mechanism of action, targeting two of the main engines driving NASH, CVC has the potential to play a differentiated role in the management of NASH and may form the cornerstone of NASH combination treatment strategies, both as a single agent and in combination with other agents targeting metabolic pathways. CVC has been granted Fast Track status in patients with NASH and liver fibrosis, the patient population at highest risk of progression to cirrhosis.




Krishan Maggon 's insight:
Cenicriviroc (CVC) is currently in clinical development for non-alcoholic steatohepatitis (NASH) in adults with liver fibrosis and primary sclerosing cholangitis (PSC). Over 600 unique subjects have been exposed to CVC in completed studies, including 440 subjects participating in Phase 1 studies and 159 HIV infected subjects participating in Phase 2 studies. 

 CVC is a dual inhibitor of the CCR2 and CCR5 pathways which play a key role in the cycle of inflammation and fibrosis. CVC has been shown in clinical trials to bind to both CCR2 and CCR5 targets.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Human immune response to Hepatitis C virus Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital. - ppt download

Human immune response to Hepatitis C virus Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital. - ppt download | Hepatitis C New Drugs Review | Scoop.it
Human immune response to Hepatitis C virus Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

World Hepatitis Day — July 28, 2016 | MMWR

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC).
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection | Hepatitis C New Drugs Review | Scoop.it
The prevalence of Hepatitis C Virus (HCV) infection is significantly higher in patients with end-stage renal disease compared to the general population and poses important clinical challenges in patients who undergo kidney transplantation. Historically, interferon-based treatment options have been limited by low rates of efficacy and significant side effects, including risk of precipitating rejection. Limited data exist on the use of all-oral, interferon-free direct-acting antiviral (DAA) therapies in kidney transplant recipients. In this study, we performed a retrospective chart review with prospective clinical follow-up of post-kidney transplant patients treated with DAA therapies at three major hospitals in Boston, MA. A total of 24 kidney recipients with HCV infection received all-oral DAA therapy post-transplant. Patients were predominantly male (79%) with a median age of 60 years (range 34–70 years), median creatinine of 1.2 mg/dL (0.66–1.76), and 42% had advanced fibrosis or cirrhosis. The majority had HCV genotype 1a infection (58%). All patients received full-dose sofosbuvir; it was paired with simeprevir (9 patients without and 3 patients with ribavirin), ledipasvir (7 patients without and 1 patient with ribavirin) or ribavirin alone (4 patients). The overall sustained virologic response (SVR12) was 91% (21 out of 23 patients). One patient achieved SVR4 but demised prior to SVR12 check point due to treatment unrelated cause. Two treatment failures were successfully retreated with alternative DAA regimens and achieved SVR. Both initials failures occurred in patients with advanced fibrosis or cirrhosis, with genotype 1a infection, and prior HCV treatment failure. Adverse events were reported in 11 patients (46%) and were managed clinically without discontinuation of therapy. Calcineurin inhibitor trough levels did not significantly change during therapy. In this multi-center series of patients, all-oral DAA therapy appears to be safe and effective in post-kidney transplant patients with chronic HCV infection.
Krishan Maggon 's insight:
Citation: Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, et al. (2016) Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS ONE 11(7): e0158431. doi:10.1371/journal.pone.0158431
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

NHS England » World Hepatitis Day: a chance to reflect on achievements to date and redouble efforts – Peter Huskinson and Professor Graham Foster

Health and high quality care for all,
now and for future generations
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Genotyping: Therapeutic Implications | MEDCHROME

Hepatitis C Genotyping: Therapeutic Implications | MEDCHROME | Hepatitis C New Drugs Review | Scoop.it
    The hepatitis C virus (HCV) is a RNA virus belonging to the Flaviviridae family which causes viral hepatitis, a systemic infection affecting
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Is Europe ready to eliminate viral hepatitis?

Is Europe ready to eliminate viral hepatitis? | Hepatitis C New Drugs Review | Scoop.it
The goal for 2030: a world free of hepatitis. Currently, Europe records around 57 000 newly diagnosed acute and chronic cases of hepatitis B and C each year. On top of that, an estimated 10 million Europeans are believe
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

MEDGENERA | Advances in Hepatitis C Drug Development: An Industrial Update

MEDGENERA | Advances in Hepatitis C Drug Development: An Industrial Update | Hepatitis C New Drugs Review | Scoop.it
On World Hepatitis Day, we reviewed the hepatitis and global hepatitis c drug discovery pipeline in 2016
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

World Hepatitis Day: A global movement for hepatitis elimination

World Hepatitis Day: A global movement for hepatitis elimination | Hepatitis C New Drugs Review | Scoop.it
Viral hepatitis is the inflammation of the liver brought about by the infection of one of five viruses known as hepatitis A, B, C, D, or E.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

NHS 'abandoning' thousands by rationing hepatitis C drugs

NHS 'abandoning' thousands by rationing hepatitis C drugs | Hepatitis C New Drugs Review | Scoop.it
Addaction says NHS England decision to treat just 10,000 people a year with costly drugs is ‘potential death sentence’
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Discovery of new Hepatitis C Virus mechanism - Scienmag

Discovery of new Hepatitis C Virus mechanism - Scienmag | Hepatitis C New Drugs Review | Scoop.it
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus (HCV) with the potential of improving pathological liver conditions. Using model ..
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Artes Biotechnology and Burnet Institute join forces to develop novel hepatitis C vaccine

Artes Biotechnology and Burnet Institute join forces to develop novel hepatitis C vaccine | Hepatitis C New Drugs Review | Scoop.it
The project will combine Burnets HepSeeVaxDelta3 technology with Artes’ Metavax technology
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Harvoni Sales Declines Hurt Gilead Sciences Inc. in Q2 -- The Motley Fool

Harvoni Sales Declines Hurt Gilead Sciences Inc. in Q2  --  The Motley Fool | Hepatitis C New Drugs Review | Scoop.it
Disappointing revenue and earnings for this big biotech stem from big drops in sales for its top drug, Harvoni.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Drug Trend Report | Express Scripts

Drug Trend Report | Express Scripts | Hepatitis C New Drugs Review | Scoop.it
Drug Trend Report

mproving Patient Care, Decreasing Spend Hepatitis C treatment was a leading reason why drug spending increased in 2014 at the highest rate in more than [...] However, payers enrolled in Express Scripts’ Hepatitis Cure Value Program®
Krishan Maggon 's insight:
IMS Health
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials - Tacke - Liver International - Wiley Online Library

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials - Tacke - Liver International - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Treatment of HCV G2 with SOF+RBV results in lower SVR rates in real life than expected from clinical trials https://t.co/OoUXErK3s6
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

3 Enormously Important Things You Won't See in Gilead Sciences' Q2 Results -- The Motley Fool

3 Enormously Important Things You Won't See in Gilead Sciences' Q2 Results --  The Motley Fool | Hepatitis C New Drugs Review | Scoop.it
These are the critical items investors should care about that won't be obvious in this big biotech's Q2 results.
more...
No comment yet.